Profile data is unavailable for this security.
About the company
Nextage Therapeutics Ltd, formerly known asMicromedic Technologies Ltd,is an Israel-based company engaged in the development and commercialization of cancer diagnostic products. Its portfolio includes a range of cancer and cancer-related indications including colorectal cancer, breast cancer, cervical cancer, bladder cancer, lung cancer, and diagnostic tools for personalized treatment. Micromedic forms a cluster that manages the development of a variety of products across the cancer diagnostic value chain. From screening and risk identification, through diagnostics, personalized medicine, and monitoring disease recurrence, Micromedic identifies projects that fill unmet needs in various cancer related indications, and turns them into viable marketable products. Micromedic operates through strategic collaborations and in-licensing from scientific institutes world-wide as well as in-house based research.
- Revenue in ILS (TTM)1.02m
- Net income in ILS-3.36m
- Incorporated1982
- Employees--
- LocationNextage Therapeutics LtdEtzel Nexter, Einstein B13, K.1TEL AVIV-YAFO 6158101IsraelISR
- Phone+972 35756917
- Fax+972 35756919
- Websitehttps://m-medic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merchavia Holdings and Investments Ltd | 1.90m | -9.48m | 11.10m | 1.23k | -- | 1.70 | -- | 5.86 | -3.51 | -3.51 | 0.175 | 0.3884 | 0.0497 | -- | 14.75 | 1,543.16 | -24.85 | -3.37 | -25.66 | -3.46 | -- | -- | -500.16 | -185.15 | -- | -0.1024 | 0.00 | -- | 90.08 | -10.25 | -349.99 | -- | 37.97 | -- |
| Purple Biotech Ltd | 0.00 | -59.33m | 17.85m | 20.00 | -- | 0.1412 | -- | -- | -0.2167 | -0.2167 | 0.00 | 0.3443 | 0.00 | -- | -- | 0.00 | -38.33 | -37.24 | -44.43 | -41.28 | -- | -- | -- | -9,415.70 | -- | -- | 0.0088 | -- | -- | -- | 8.25 | -- | -28.45 | -- |
| Nextage Therapeutics Ltd | 1.02m | -3.36m | 27.56m | -- | -- | -- | -- | 26.97 | -0.1057 | -0.1057 | 0.032 | -0.1293 | 1.58 | -- | 10.32 | -- | -553.86 | -188.94 | -- | -423.76 | 22.60 | 33.33 | -351.17 | -2,486.19 | -- | -65.46 | -- | -- | -- | 17.99 | 30.57 | -- | -- | -- |
| Kadimastem Ltd | 0.00 | -9.68m | 53.30m | 32.00 | -- | -- | -- | -- | -2.12 | -2.12 | 0.00 | -1.94 | 0.00 | -- | -- | -- | -129.59 | -155.33 | -- | -1,831.12 | -- | -- | -- | -- | -- | -3.11 | 3.31 | -- | -- | -- | 47.14 | -- | -50.73 | -- |
| Matricelf Ltd | 0.00 | -13.66m | 63.81m | -- | -- | 2.96 | -- | -- | -0.8738 | -0.8738 | 0.00 | 1.34 | 0.00 | -- | -- | -- | -47.15 | -- | -50.89 | -- | -- | -- | -- | -- | -- | -- | 0.057 | -- | -- | -- | -10.77 | -- | -- | -- |
| X T L Biopharmaceuticals Ltd | 1.68m | -83.24m | 80.87m | 33.00 | -- | 0.4222 | -- | 48.13 | -0.378 | -0.378 | 0.0076 | 0.1527 | 0.0192 | -- | 0.7012 | 50,918.16 | -94.96 | -53.17 | -111.98 | -59.10 | -- | -2.33 | -4,953.75 | -1,084.42 | -- | -- | 0.00 | -- | -85.80 | -- | -7.97 | -- | -53.12 | -- |
| DNA Group TR Ltd | 306.00k | 15.05m | 110.60m | 14.00 | 7.35 | 1.13 | -- | 361.44 | 0.1222 | 0.1222 | 0.0025 | 0.7981 | 0.0033 | -- | 1.44 | 21,857.14 | 16.35 | -23.54 | 16.48 | -26.27 | -- | -- | 4,918.63 | -7,406.24 | -- | -- | 0.00 | -- | -45.36 | -- | 95.00 | -- | -- | -- |
| BioLine RX Ltd | 43.14m | -181.90m | 127.34m | 79.00 | -- | 2.39 | -- | 2.95 | -0.1882 | -0.1882 | 0.043 | 0.0445 | 0.1939 | -- | 6.40 | 546,029.40 | -81.75 | -52.74 | -127.94 | -65.43 | 55.84 | -- | -421.69 | -3,501.79 | 1.05 | -519.43 | 0.4642 | -- | -- | -- | -142.93 | -- | -50.72 | -- |
| Bonus Biogroup Ltd | 0.00 | -29.19m | 134.31m | 58.00 | -- | 8.72 | -- | -- | -0.0718 | -0.0718 | 0.00 | 0.0132 | 0.00 | -- | -- | 0.00 | -64.14 | -76.10 | -74.97 | -97.19 | -- | -- | -- | -- | -- | -- | 0.4106 | -- | -- | -- | 26.29 | -- | 19.30 | -- |
